Becaplermin Articles
EMEA recommends Janssen-Cilag’s Regranex not be used in patients with any pre-existing cancer
19 February 2010
J&J unit gets offer for Wound Care business
7 July 2008
Cancer death risk label for J&J's Regranex
16 June 2008
FDA launches safety review of J&J's Regranex
7 April 2008
Euro advanced wound- healing market set to grow 12.4%/year
24 January 2005
Smith & Nephew buys BASF's wound-care product, takes market lead
3 February 2000
J&J's Regranex cleared in EU
15 April 1999
-Ortho-McNeil's Regranex approved by Health Canada
4 March 1999
J&J's Regranex Launched In USA
21 April 1998
J&J 1st Quarter Earnings Rise But Strong $ Hits Sales
15 April 1998
Strong Growth For US Drug Firms In 1997
28 January 1998
Rapid Advances In Wound-Healing Industry
13 January 1998
New Products In 1998; A Look Ahead
6 January 1998
First Approval Of Regranex Gel For Foot Ulcers
18 December 1997
Chiron And J&J File BLA For Regranex Gel
20 January 1997
Winners And Losers In US Medicare/Medicaid Reform
20 November 1995
Showing 1-22 of 22 articles
- 1
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
